Cargando…

Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Insights From the SHaRe Registry

The term “end stage” has been used to describe hypertrophic cardiomyopathy (HCM) with left ventricular systolic dysfunction (LVSD), defined as occurring when left ventricular ejection fraction is <50%. The prognosis of HCM-LVSD has reportedly been poor, but because of its relative rarity, the nat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marstrand, Peter, Han, Larry, Day, Sharlene M., Olivotto, Iacopo, Ashley, Euan A., Michels, Michelle, Pereira, Alexandre C., Wittekind, Samuel G., Helms, Adam, Saberi, Sara, Jacoby, Daniel, Ware, James S., Colan, Steven D., Semsarian, Christopher, Ingles, Jodie, Lakdawala, Neal K., Ho, Carolyn Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182243/ https://www.ncbi.nlm.nih.gov/pubmed/32228044 http://dx.doi.org/10.1161/CIRCULATIONAHA.119.044366

Ejemplares similares

Left Ventricular Systolic Dysfunction in Patients Diagnosed With Hypertrophic Cardiomyopathy During Childhood: Insights From the SHaRe Registry
por: Abou Alaiwi, Sarah, et al.
Publicado: (2023)

Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy
por: Marston, Nicholas A, et al.
Publicado: (2021)

Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretation
por: Thompson, Andrea D., et al.
Publicado: (2021)

Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)
por: Ho, Carolyn Y., et al.
Publicado: (2018)

Spatial and Functional Distribution of MYBPC3 Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy
por: Helms, Adam S., et al.
Publicado: (2020)

Temporal Trend of Age at Diagnosis in Hypertrophic Cardiomyopathy: An Analysis of the International Sarcomeric Human Cardiomyopathy Registry
por: Canepa, Marco, et al.
Publicado: (2020)

External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy
por: Norrish, Gabrielle, et al.
Publicado: (2021)

Sex Differences in Hypertrophic Cardiomyopathy: Interaction With Genetics and Environment
por: Butters, Alexandra, et al.
Publicado: (2021)

Development of a communication aid for explaining hypertrophic cardiomyopathy genetic test results
por: Smagarinsky, Yana, et al.
Publicado: (2017)

Sex‐Related Differences in Genetic Cardiomyopathies
por: Argirò, Alessia, et al.
Publicado: (2022)

Physical activity in hypertrophic cardiomyopathy: prevalence of inactivity and perceived barriers
por: Sweeting, Joanna, et al.
Publicado: (2016)

Evaluating a custom-designed aid to improve communication of genetic results in families with hypertrophic cardiomyopathy: study protocol for a randomised controlled trial
por: Burns, Charlotte, et al.
Publicado: (2019)

Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: the case of hypertrophic cardiomyopathy
por: Walsh, Roddy, et al.
Publicado: (2019)

INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy—a Randomised Intervention Trial with losartan)
por: Olivotto, Iacopo, et al.
Publicado: (2015)

Sha /
por: Vázquez-Figueroa, Alberto
Publicado: (1980)

Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy
por: Toepfer, Christopher N., et al.
Publicado: (2020)

Clinical Phenotype and Outcome of Hypertrophic Cardiomyopathy Associated With Thin-Filament Gene Mutations
por: Coppini, Raffaele, et al.
Publicado: (2014)

Getting inside the engine - myosin modulation in hypertrophic cardiomyopathy and systolic heart failure
por: Daniels, Matthew J, et al.
Publicado: (2021)

Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy
por: Braunwald, Eugene, et al.
Publicado: (2023)

Molecular autopsy in victims of inherited arrhythmias
por: Semsarian, Christopher, et al.
Publicado: (2016)

Disease-specific variant pathogenicity prediction significantly improves variant interpretation in inherited cardiac conditions
por: Zhang, Xiaolei, et al.
Publicado: (2020)

Impact of SARS‐Cov‐2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry
por: Gimeno, Juan R., et al.
Publicado: (2022)

Impact of Demographic Features, Lifestyle, and Comorbidities on the Clinical Expression of Hypertrophic Cardiomyopathy
por: Finocchiaro, Gherardo, et al.
Publicado: (2017)

A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy
por: Miron, Anastasia, et al.
Publicado: (2020)

Microvascular Dysfunction in Hypertrophic Cardiomyopathy
por: Pelliccia, Francesco, et al.
Publicado: (2022)

The systolic paradox in hypertrophic cardiomyopathy
por: Haland, Trine F, et al.
Publicado: (2017)

Routinely collected health data to study inherited heart disease: a systematic review (2000–2016)
por: Blanch, Bianca, et al.
Publicado: (2017)

Diagnostic and prognostic electrocardiographic features in patients with hypertrophic cardiomyopathy
por: Bernardini, Andrea, et al.
Publicado: (2023)

Constitutive Law Identification and Fatigue Characterization of Rigid PUR Elastomers 80 ShA and 90 ShA
por: Junik, Krzysztof, et al.
Publicado: (2022)

Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter
por: Masri, Ahmad, et al.
Publicado: (2022)

Hypertrophic cardiomyopathy: The need for randomized trials
por: Olivotto, Iacopo, et al.
Publicado: (2013)

Genetic profile of hypertrophic cardiomyopathy in Tunisia: Is it different?
por: Jaafar, Nawel, et al.
Publicado: (2015)

Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes
por: Ingles, Jodie, et al.
Publicado: (2019)

Doctor-patient care relationship in genetic cardiomyopathies: An exploratory study on clinical consultations
por: Fioretti, Chiara, et al.
Publicado: (2020)

Needs analysis of parents following sudden cardiac death in the young
por: McDonald, Kristie, et al.
Publicado: (2020)

Stage-specific therapy for hypertrophic cardiomyopathy
por: Argirò, Alessia, et al.
Publicado: (2023)

Life-long tailoring of management for patients with hypertrophic cardiomyopathy: Awareness and decision-making in changing scenarios
por: Michels, M., et al.
Publicado: (2016)

El Sha o la desmesura del poder /
por: Kapuściński, Ryszard
Publicado: (1987)

Simulation Analysis and Comparison of New Hybrid TLI-µTESLA and Variant TESLA Protocols Using SHA-2 and SHA-3 Hash Functions
por: Eledlebi, Khouloud, et al.
Publicado: (2022)

Inflammation across the spectrum of hypertrophic cardiac phenotypes
por: Lillo, Rosa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b8ero975g32ig7ot4pbqkpf7e6